Novartis (NOVN.VX) Financials

Summary - Funding Rounds

Founding Date

Novartis is a subsidiary of GlaxoSmithKline


Income Statement


USDFY, 2014FY, 2015FY, 2016


53.6 b49.4 b48.5 b

Revenue growth, %


Cost of goods sold

17.3 b17.4 b17.5 b

Gross profit

36.3 b32 b31 b

Gross profit Margin, %


Sales and marketing expense

12.4 b11.8 b12 b

R&D expense

9.1 b8.9 b9 b

General and administrative expense

2.6 b2.5 b2.2 b

Operating expense total

25.2 b24 b23.6 b

Interest expense

704 m655 m707 m

Interest income

31 m454 m447 m

Net Income

10.3 b17.8 b6.7 b

Cash Flow


USDFY, 2015FY, 2016

Cash From Operating Activities

12.1 b11.5 b
Report incorrect company information

Operating Metrics

Y, 2015Y, 2016

Major Approvals (US, EU, JP)

20 16

Major Submissions (US, EU, JP)

14 24

Patients Reached

972 m965 m

Phase III Trials Products

37 29

Projects Entering Development Pipeline

8 5

US FDA Breakthrough Therapy Designations

Report incorrect company information